Beautiful Virgin Islands

Tuesday, Jul 01, 2025

Even more evidence shows vaccinated people are unlikely to transmit the coronavirus or get asymptomatic infections

Even more evidence shows vaccinated people are unlikely to transmit the coronavirus or get asymptomatic infections

A new study shows that Pfizer's shot prevents asymptomatic infections almost as well as symptomatic cases of COVID-19.

Once effective coronavirus vaccines were authorized and started getting distributed, the crucial question became: Do they stop transmission?

In clinical trials, Pfizer and Moderna showed that their shots prevent symptomatic COVID-19, but they didn't test whether their vaccines prevent asymptomatic cases. Without curtailing symptom-less infections, it's difficult to stop transmission from person to person. But a growing body of evidence suggests that people who get these vaccines don't spread the virus after all.

Pfizer announced Thursday that its vaccine appears to be 94% effective at preventing asymptomatic infections two weeks after people receive their second dose. The study compared unvaccinated people in Israel to those who got the Pfizer shot between January 17 and March 6.

The findings are "particularly meaningful as we look to disrupt the spread of the virus around the globe," Dr. Luis Jodar, Pfizer's chief medical officer, said in a press release.

Vaccinated people may be less contagious if they get infected
People on the London Underground on September 25, 2020.

Research shows the more viral particles a person has in their mouth and nose — what's known as viral load — the more likely they are to pass the coronavirus to others. Reduced viral loads are linked to lower transmission rates.

So a vaccine should reduce transmission if it can ensure that even those who still get the coronavirus after their shots, whether a symptomatic or asymptomatic case, have a lower viral load than they would otherwise.

A February study from Israel, which has yet to be peer-reviewed, found that starting 12 days after vaccination, the people who got COVID-19 despite getting Pfizer's shots had four times less virus in their bodies.

The researchers looked at more than 1,000 people who'd tested positive for the virus after being fully vaccinated in Tel Aviv. Those people's viral loads in the period from 12 to 28 days after their second dose were four times lower than their viral loads in the first 11 days after vaccination.

Another study from Israel, also not yet peer-reviewed, suggested the Pfizer vaccine reduced viral loads by a factor of up to 20.

Some research suggests viral loads are linked to disease severity, so a patient with a lower viral load is also less likely to have severe COVID-19. That may in part explain why Pfizer's vaccine significantly reduces the chance of symptomatic infection.

Vaccinated people are less likely to develop asymptomatic infections
Dr. Jason Smith shows off his bandage after getting vaccinated at the University of Louisville Hospital in Kentucky.


To pinpoint whether vaccines truly reduce spread, it's critical to determine whether the shots prevent asymptomatic COVID-19 cases in addition to symptomatic infections.

Pfizer and Moderna's clinical trials only tested volunteers for COVID-19 if they felt ill. Otherwise, the companies would have had to require regular COVID-19 testing for all tens of thousands of volunteers. So at first, neither company could say whether their vaccines prevent asymptomatic cases.

But Moderna did test trial volunteers on the day they got their second shots. And the findings suggested that there were fewer asymptomatic infections among participants who'd received the real vaccine than among those who got a placebo. Just 14 people of the 14,000-plus in the trial's vaccine group had asymptomatic cases that day, compared to 38 of the similarly sized placebo group.

That's a 61.5% drop, according to Marm Kilpatrick, a disease ecologist at the University of California, Santa Cruz. He wrote on Twitter last month that the data suggests Moderna's vaccine blocks about 91% of transmission.

A man receives a COVID-19 vaccine at a health services center in Rehovot, Israel, on January 14, 2021.


Animal studies offer similar findings: An October paper found that the Moderna vaccine prevented the coronavirus from replicating in the nose, throat, and lungs of rhesus macaques four weeks after they'd been vaccinated. If the viral particles can't copy themselves, it's unlikely an infected host will pass on particles to others.

Before the Pfizer findings announced Thursday, a preliminary study published in The Lancet found the shot to be at least 85% effective at preventing any type of infection — symptomatic or asymptomatic. That study looked at more than 23,000 healthcare workers across hospitals in the UK.

Additionally, a recent study found that people who'd received at least one dose of a mRNA vaccine — from either Pfizer or Moderna — were 72% less likely to test positive for an asymptomatic infection 10 days after their shot, relative to unvaccinated people. The research looked at more than 39,000 Americans.

Johnson & Johnson's trial data on asymptomatic infections also seems promising. The company tested blood samples from almost 3,000 participants for coronavirus antibodies 71 days after they'd been vaccinated. (The presence of antibodies suggests participants had been infected even if they didn't show symptoms.) Only two vaccinated people tested positive, whereas 16 people who'd received a placebo did, according to data released last month from the Food and Drug Administration.

That suggests J&J's vaccine may be 74% effective against asymptomatic infections, though the FDA noted that more data is needed to be sure.

Vials of the Pfizer-BioNTech COVID-19 vaccines at Renown Health in Reno, Nevada on December 17, 2020.


Even the Oxford-AstraZeneca vaccine, which is still in clinical trials in the US, may reduce asymptomatic infections.

A February Oxford study, which has yet to be peer reviewed, found that among people who received just one dose, the number of positive COVID-19 tests — among both symptomatic and asymptomatic study participants — fell by 67%.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Robots Compete in Football Tournament in China Amid Injuries
Trump Administration Considers Withdrawal of Funding for Hospitals Providing Gender Treatment to Minors
Texas Enacts Law Allowing Gold and Silver Transactions
China Unveils Miniature Insect-Like Surveillance Drone
OpenAI Secures Multimillion-Dollar AI Contracts with Pentagon, India, and Grab
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Germany Votes to Suspend Family Reunification for Asylum Seekers
Elon Musk Critiques Senate Budget Proposal Over Job Losses and Strategic Risks
Los Angeles Riots ended with Federal Investigations into Funding
Budapest Pride Parade Draws 200,000 Participants Amid Government Ban
Southern Europe Experiences Extreme Heat
Xiaomi's YU7 SUV Launch Garners Record Pre-Orders Amid Market Challenges
Jeff Bezos and Lauren Sanchez's Lavish Wedding in Venice
Russia Launches Largest Air Assault on Ukraine Since Invasion
Education Secretary Announces Overhaul of Complaints System Amid Rising Parental Grievances
Massive Anti-Government Protests Erupt in Belgrade
Trump Ends Trade Talks with Canada Over Digital Services Tax
UK Government Softens Welfare Reform Plans Amid Labour Party Rebellion
Labour Faces Rebellion Over Disability Benefit Reforms Ahead of Key Vote
Jeff Bezos and Lauren Sánchez Host Lavish Wedding in Venice Amid Protests
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
North Korea to Open New Beach Resort to Boost Tourism Economy
UK Labour Party Faces Internal Tensions Over Welfare Reforms
Andrew Cuomo Hints at Potential November Comeback Amid Democratic Primary Results
Curtis Sliwa Champions His Vision for New York City Amid Rising Crime Concerns
Federal Reserve Proposes Changes to Capital Rule Affecting Major Banks
EU TO HUNGARY: LET THEM PRIDE OR PREP FOR SHADE. ORBÁN TO EU: STAY IN YOUR LANE AND FIX YOUR OWN MESS.
Trump Escalates Criticism of Media Over Iran Strike Coverage
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
Big Four Accounting Firms Fined in Exam Cheating Scandal
NATO Members Agree to 5% Defense Spending Target by 2035
Australia's Star Casino Secures $195 Million Rescue Package Amid Challenges
UK to Enhance Nuclear Capabilities with Acquisition of F-35A Fighter Jets
Russian Shadow Payments via Cryptocurrency Reach $9 Billion
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Macron and Merz: Europe must arm itself in an unstable world
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Airlines Evaluate Flight Cancellations Amid Escalating US-Iran Tensions
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
×